#ESMO20: Bristol Myers marks Opdivo's second adjuvant win — eyeing a standard of care gap

Moving into earlier and earlier treatment lines, Bristol Myers Squibb is reporting that adjuvant treatment with Opdivo has doubled the time that esophageal or gastroesophageal junction cancer patients stay free of disease.